Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GSK AMPK activators are active in diabetes and obesity models

April 16, 2012

New melanin-concentrating hormone receptor antagonists identified

April 16, 2012

Joint research for metabolic disease therapies advances

April 13, 2012

Lilly obtains approval in Canada for testosterone replacement therapy

April 12, 2012

Orphan drug status granted to ReGenX BioSciences program

April 12, 2012

New glucagon GLP-1 receptor agonists designed in China

April 12, 2012

Korlym now available in U.S.

April 11, 2012

Pharmos reports promising data from ongoing phase IIa trial of levotofisopam

April 10, 2012

Sclerostin-directed antibody advances to phase III for osteoporosis

April 5, 2012

Hanmi Pharmaceutical's HM-47000 selected as a government project

April 5, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...